Katrine Bosley is stepping down as CEO of Editas Medicine. Photo: Jonathan Wiggs/The Boston Globe via Getty Images

Katrine Bosley is resigning as CEO of Editas Medicine, a biotechnology company working on pathways to use the gene-editing technology known as CRISPR for human treatments. The unexpected news drove down the company's stock price by 22%.

The big picture: Bosley's departure is not a good look for Editas, which bid adieu to its chief financial and medical officers in the past month. Gene editing has attracted controversy over the past few months, but Editas recently got federal approval to work on a small clinical trial to test the safety, tolerability and efficacy of a gene-editing medicine in patients who have a rare eye disorder.

Go deeper

Child care crisis is denting the labor market

Reproduced from Pew Research Center; Chart: Axios Visuals

New data from the Pew Research Center shows that parents are being hit especially hard by the coronavirus pandemic, and as far as job losses go, mothers and fathers are faring equally poorly.

Why it matters: Economists have been warning for months that the pandemic could do long-term damage to the economy as people remain unemployed for longer stretches of time.

Mike Allen, author of AM
2 hours ago - Politics & Policy

Trump-Biden venom on display during final debate

Photos: Brendan Smialowski/AFP via Getty Images; Jim Watson/AFP via Getty Images

Joe Biden twice referred to President Trump as "this guy," and Trump called the former vice president's family "like a vacuum cleaner" for foreign money.

Why it matters: The personal venom — during Thursday's final presidential debate, in Nashville — was a reminder that even during a more normal debate, nothing this year is normal.

Dave Lawler, author of World
3 hours ago - World

Special report: Trump's hopes of nuclear deal with Putin come down to the wire

Illustration: Lazaro Gamio/Axios

A surprise offer from Vladimir Putin has the U.S. and Russia once again circling a potential pre-election nuclear deal.

The big picture: The last treaty constraining the U.S. and Russia, New START, is due to expire on Feb. 5, 2021, two weeks after the next U.S. presidential inauguration. For the first time since the height of the Cold War, the nuclear guardrails could come off.